**UNITED STATES**
**SECURITIES AND EXCHANGE COMMISSION**
**Washington, D.C. 20549**

# FORM 8-K

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF**
**THE SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported): **September 16, 2024**

# VolitionRx Limited

(Exact name of registrant as specified in its charter)

| **Delaware** | **001-36833** | **91-1949078** |
|---|---|---|
| (State or other jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification Number) |

| **1489 West Warm Springs Road, Suite 110 Henderson, Nevada** | **89014** |
|---|---|
| (Address of Principal Executive Offices) | (Zip Code) |

**+1 (646) 650-1351**
(Registrant's telephone number, including area code )

**Not applicable**
(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

| **Title of Each Class** | **Trading Symbol(s)** | **Name of Each Exchange on which Registered** |
|---|---|---|
| Common Stock, par value $0.001 per share | VNRX | NYSE American, LLC |

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 ofthe Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐

**Item 7.01. Regulation FD Disclosure.**

From September 16, 2024, VolitionRx Limited (the "Company") is making available to third parties, including through its licensing adviser, PharmaVentures Limited, a document providing a brief introduction to certain components of the Company's oncology portfolio available to out license. A copy of the document is furnished hereto as Exhibit 99.1 to this Current Report on Form 8-K and incorporated in this Item 7.01 in its entirety.

The information contained in, or incorporated into, this Item 7.01 is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any registration statement or other filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference to such filing.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits.

| **Exhibit Number** | **Description** |
|---|---|
| 99.1 | Brief Overview of Certain Oncology Assets, issued September 16, 2024. |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL (eXtensible Business Reporting Language) document) |

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**VOLITIONRX LIMITED**

Date: September 16, 2024

By: */s/ Cameron Reynolds*
Cameron Reynolds
Chief Executive Officer & President

**EXHIBIT INDEX**

| Exhibit Number | Description |
|---|---|
| 99.1 | Brief Overview of Certain Oncology Assets, issued September 16, 2024. |

# Volition

## New Generation of Cancer Diagnostics: Multiple Licensing Opportunities

PharmaVentures
the deal experts

**Adrian Dawkes**
**Managing Director**
**Adrian@pharmaventures.com**

**Volition's technologies are next-generation cancer diagnostics which analyze circulating tumor derived nucleoproteins by immunochemistry.**

**Nu.Q®** is a platform of rapid and low-cost Nucleosomics™ immunoassays targeting cancer associated nucleoproteins in plasma with applications in Multi-Cancer Early Detection (MCED), differentiation of malignant and benign nodules identified on Non-Small Cell Lung Cancer (NSCLC) screening, Minimal Residual Disease (MRD) and treatment monitoring.

The Volition Nu.Q® Vet Cancer Test is currently licensed to two of the largest veterinary service companies world-wide.

nu·q

**Measuring blood-based nucleosomes and their post-translational modifications as novel cancer biomarkers**

- ✓ High clinical accuracy, low cost, low sample volume and rapid turnaround time.
- ✓ Automated magnetic chemiluminescence (ChLIA) immunoassay system.
- ✓ Validation of malignant or benign lung nodule test currently underway with hospital centres in Taiwan.
- ✓ MRD validation currently underway with hospital centres in France.
- ✓ Potential large and growing market opportunity in NSCLC.

## Nu.Q® MCED[1].

In an initial study of 7 cancer types in 100 cancer and 73 healthy subjects, Volition's Nu.Q® MCED immunoassay detects all cancer types studied, including more than 30% of stage I solid tumors at 100% specificity.




## Nu.Q® MRD/Treatment Monitor[2].

- Increased the detection of MRD from 43% to 58%.
- Decreased the number of false negatives identified with current methods.
- Facilitates enhanced detection of patients not responding to current treatment.
- Nu.Q® has potential for use before ctDNA analysis.




## Nu.Q® Lung Nodule Test[3].

- Nu.Q® discriminated between benign and malignant lung cancer nodules discovered in lung cancer screening by Low Dose CT imaging.
- May reduce unnecessary biopsies by up to 50%.



AUC=79%

**1.2M**
NSCLC Patients Diagnosed Annually

**89M**
Potential Tests for screening MRD & Treatment Monitoring Annually

## Volition's technology isolates CTCF-associated ctDNA from non-tumor derived background for the detection of cancer-specific sequences

A new class of non-nucleosomal ctDNA molecules invisible to conventional Next Generation Sequencing (NGS).

Immunochemical isolation enriches ctDNA fragment sequences to near 100% purity, tackling the cfDNA "noise" in current liquid biopsies.

Isolated ctDNA sequences may then be analyzed by NGS or by simple PCR.

Initial patient studies using Capture-PCR™ showed detection of all cancers tested including more than a third of stage I cancer cases[4].




# Development Status

| Program | PoC | Validation | Viability |
|---|---|---|---|
| Nu.Q® MRD and Treatment Monitoring | NSCLC | | |
| | Other Cancers | | |
| Nu.Q® Lung Screening | | | |
| Nu.Q® MCED | | | |
| Capture PCR™ | | | |

# Patent Portfolio

**Strong company focus on IP**

In total:

- 86 patents granted
- 128 pending internationally

All technologies described are subject to patent filings

Patent coverage up to 2044


1. Data on file
2. ELCC 2024: S. Couraud, Baseline values of circulating nucleosomes in Lung Cancer: NUCLEO-LUNG STUDY
3. Data on file
4. ESMO 2023:D.Pamart et al, A novel immunoprecipitation/PCR method for detection of plasma cfDNA fragments selectively occupied by CTCF in cancer